Later on, ctDNA has been used in advanced breast cancer to detect PIK3CA mutations as resistance to cyclin kinase inhibitors [56], and, more recently, for the detection of ESR1 mutations [57]. This evidence concerns the gene PIK3CA and breast carcinoma.